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Objectives. This study assessed the effects of digoxin and 
ibopamine on variables of heart rate variability in relation to 
neurohormonal activation. 
Background. Analysis of heart rate variability can be used to 
study the autonomic dysfunction that characterizes chronic heart 
failure. In the Dutch Ibopamine Multicenter Trial, patients with 
heart failure were found to have increased neurohormonal acti- 
vation with placebo therapy but not with digoxin and ibopamine 
therapy. 
Methods. We studied 59 patients with mild to moderate heart 
failure (mean [-+SEM] age 60 - 1 years, mean ejection fraction 
0.30 _+ 0.01). Patients were randomized to double-blind treatment 
with digoxin (0.25 mg [n = 22]), ibopamine (100 mg three times 
a day [n = 19]) or placebo (n = 18); background therapy 
consisted of furosemide (up to 80 rag). 
Results. After 3 months, plasma norepinephrine levels had 
increased with placebo, whereas they decreased with digoxin (+ 31 
vs. -60 pg/ml, respectively, p < 0.01). With ibopamine, a nonsig- 
nificant decrease was observed (-27 pg/ml, p = 0.10). All 
variables of heart rate variability showed a deterioration in the 
placebo group. With digoxin, the percent differences between 
successive RR intervals > 50 ms (pNN50) increased (+ 1.7 -- 0.9%, 
p < 0.01), along with absolute and normalized high frequency 
power (+40 _+ 33 ms 2, p < 0.05 and +2.4 -+ 1.7%, p < 0.01, 
respectively). These changes were observed during daytime hours 
only and were most pronounced in patients with the most im- 
paired baseline heart rate variability. With ibopamine, nonsignif- 
icant trends similar to the changes with digoxin were observed. 
Conclusions. In patients with early stages of heart failure, 
digoxin may prevent a progressive deterioration in heart rate 
variability, whereas ibopamine does not show statistically signif- 
icant effects. The changes in heart rate variability with digoxin 
parallel an observed decrease in neurohormonal activation. 
Digoxin apparently enhances cardiac vagal tone in the setting of 
neuroendocrine activation. 
(J Am CoU Cardiol 1995;26:983-90) 
It has been recognized that neurohormonal ctivation is one of 
the hallmarks of chronic heart failure and that the degree of 
neurohormonal ctivation is strongly correlated with the se- 
verity and prognosis of the syndrome (1,2). Furthermore, 
chronic heart failure is associated with autonomic dysfunction 
that is characterized by increased sympathetic and decreased 
parasympathetic activity (3). Analysis of heart rate variability 
can be used to study autonomic function noninvasively (4-6), 
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and several studies have shown abnormalities of heart rate 
variability in patients with heart failure (7-12). The impair- 
ment of heart rate variability appears to be related to the 
degree of neurohormonal ctivation (7,10), which may have 
prognostic value (13). This concept herefore suggests that 
analysis of heart rate variability could be used to assess the 
severity of heart failure. At present, data on the effect of drug 
therapy on variables of heart rate variability in patients with 
heart failure are limited (14-17). Moreover, although it has 
been suggested that neurohormonal modulation by drug treat- 
ment may favorably affect heart rate variability in patients with 
heart failure, no placebo-controlled studies have compared the 
effects of pharmacologic treatment on both heart rate variabil- 
ity and neurohormonal ctivation. 
In a recently reported ouble-blind, placebo-controlled trial 
(18), we assessed the efficacy and safety of treatment with 
digoxin and the oral dopamine agonist ibopamine in patients 
with mild to moderate heart failure. The data showed that 
during long-term follow-up, both digoxin and ibopamine pre- 
vented an increase in neurohormonal ctivation but placebo 
did not. The purpose of the present s udy was to assess the 
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effects of both drugs on variables of heart rate variability and 
to investigate the relation of these effects to changes in 
neurohormonal ctivation. 
Methods  
Study design. The Dutch Ibopamine Multicenter Trial 
(DIMT) was a multicenter, double-blind, randomized, 
parallel-group comparison of ibopamine (100 mg three times 
daily), digoxin (0.25 mg once daily) and placebo in patients 
with mild to moderate heart failure. After a placebo run-in 
period of 7 to 10 days, patients received double-blind treat- 
ment. A double-dummy technique was used to ensure the 
blinding procedure. At the end of the placebo run-in period, 
and after 3 months of treatment, 24-h ambulatory Holter 
monitoring for analysis of heart rate variability and blood 
samples for determination f neurohormonal ctivation were 
obtained. The protocol was approved by the ethics committee 
of each participating center and was conducted in accordance 
with the revised Declaration of Helsinki. Before entry into the 
study, all patients gave written informed consent. 
Study group. Patients 18 to 75 years old with New York 
Heart Association functional class II or III heart failure and 
clinically stable for at least 2 weeks before the study were 
selected for inclusion in the trial. Chronic heart failure was 
characterized by clinical signs and symptoms and a radionu- 
clide left ventricular ejection fraction -<0.45 (obtained within 
the previous 2 months). In addition, patients had to be able to 
exercise for at least 4 min at 70 W on a bicycle ergometer. 
During the trial, furosemide (up to 80 mg/day) was allowed 
as background therapy, as well as short-acting nitrates. 
Triamterene was also permitted to control serum potassium 
levels. Other drugs for treatment of heart failure, including 
vasodilators and angiotensin-converting en~me inhibitors, 
alpha- or beta-adrenergic blocking agents and calcium antag- 
onists were not allowed. Patients were excluded from partici- 
pation if they had heart failure due to hemodynamically 
significant valvular or congenital heart disease, active myocar- 
ditis, thyroid disease or hypertrophic obstructive cardiomyop- 
athy. Further exclusion criteria were exercise-limiting angina 
pectoris; myocardial infarction or major operation within the 
previous 2 months; severe hypertension; atrial fibrillation or 
flutter; pacemaker therapy; a history of sustained ventricular 
tachyarrhythmias, chronic obstructive lung disease, severe he- 
patic or renal disease, insulin-dependent diabetes mellitus, 
psychiatric illnesses and use of monoamine oxidase inhibitors 
or (anti-)dopaminergic agents. 
Neurohormonal levels. Venous blood for determination of
plasma neurohormonal levels was drawn after 30 min of supine 
rest. Plasma norepinephrine, aldosterone and renin concentra- 
tions were analyzed in a central core laboratory. Plasma 
norepinephrine (19) and plasma renin (20) were measured as 
described previously; aldosterone was measured by a commer- 
cially available radioimmunoassay kit (Aldokit, Labservice 
Benelux, Apeldoorn, The Netherlands). 
Table 1. Definitions of Variables of Heart Rate Variability 
Variable Definition 
Time domain 
Mean NN (ms) 
SDNN (ms) 
cv(~) 
rMSSD (ms) 
pNN50 (~) 
Frequency domain 
TP(abs) (ms 2) 
LF(abs) (ms:) 
HF(abs) (ms 2) 
LF(nu) (9~) 
HF(nu) (%) 
LF/HF ratio 
Mean value of all normal RR intervals during 24 h 
Standard deviation ofall normal RR intervals during 
24 h 
Coelficient ofvariance, calculated as(SDNN/mean 
NN) x 100% 
Root mean square of successive difference; square root 
of mean value of squared differences between 
successive normal RR intervals 
Percent differences between successive normal RR 
intervals >50 ms 
Total power (absolute units); energy inpower 
spectrum between 0.0033 and 0.40 I-Iz 
Low frequency power (absolute units); energy inpower 
spectrum between 0.04 and 0.15 Hz 
High frequency power (absolute units); energy in
power spectrum between 0.15 and 0.40 Hz 
Low frequency power (normalized units); calculated as
{LF(abs)/[TP(abs) - Power <0.03 Hz]} x 100% 
High frequency power (normalized units); calculated as
{HF(abs)/[TP(abs) - Power <0.03 l-Iz]} x 100% 
Ratio of low to high frequency power 
Analysis of heart rate variability. The 24-h ambulatory 
Holter recordings were analyzed on a Marquette 8000 Holter 
system (Marquette Electronics) by an experienced analyst 
(J.H.) and supervised by a single physician (J.B.). The analyses 
were performed without knowledge of the administered study 
medication. Recordings with >15% noise or ectopic beats 
were excluded from heart rate variability analysis. For calcu- 
lation of variables of heart rate variability, a data base of RR 
intervals was transferred to a personal computer. Time and 
frequency domain variables were calculated from the time 
series of RR intervals (Table 1) and were computed over 
consecutive 5-min segments. Segments with >15% noise or 
ectopic beats were excluded from analysis. Before calculation 
of the frequency domain variables in the other segments, 
episodes with noise and ectopic beats were substituted by 
holding the previous normal RR interval constant throughout 
the entire period. Spectral nalysis was performed using the 
discrete Fourier transform algorithm (21-23). During spectral 
analysis, the recordings were controlled for differences in 
actual heart rate. Low and high frequency components of the 
power spectrum were calculated in absolute units. Low and 
high frequency power were also expressed in normalized units 
analogous to calculations used in autoregressive models. Fur- 
thermore, the ratio of low to high frequency power which is 
considered a measure of sympathovagal balance, was calcu- 
lated (6,23). 
Statistical analysis. Statistical analysis was performed us- 
ing SPSS-PC Version 5.01. Results are presented as mean 
value _+ SEM. Differences between treatment groups were 
analyzed by comparing the change from baseline with use of 
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Table 2. Baseline Characteristics of the Three Treatment Groups 
Placebo Digoxin lbopamine 
(n :: 18) (n = 22) (n = 19) 
Age (yr) 62 + 1 60 _+ 1 60 + 1 
Gender (%) 
Male 85 92 82 
Female 15 8 18 
Left ventricular ejection fraction (!.31 + 0.01 0.28 _+ 0.01 0.30 _+ 0.02 
New York Heart Association functional class (%) 
II 79 80 85 
Il l 21 20 15 
Cause of heart fidlure (¢:;) 
lschcmic 77 73 85 
Idiopathic 23 27 15 
Hemodynamic data 
Systolic blood pressure (ram Hg) 134 ~ 3 130 % 3 135 _+ 3 
Diastolic blood pressure (mm Hg) 83 ~ 2 81 +- 1 82 +- I 
Heart rate (beats/rain) 82 + 3 81 + 2 80 _+ 2 
Furosemide use (ms/day) 26 2 4 23 -+- 4 31 -+ 5 
Plasma neurohormonc levels* 
Norepinephrine (p~,ml) 391 (125-838) 463 (75-999) 422 (119-1,321) 
Aldosterone (p~/ml) 911 (17-436) 104 (7-416) 97 (14-498) 
Renin (ngjml per hi 22 (3-112) 28 (4-82) 23 (448)  
Hearl rate variability 
Time domain variables 
NN (ms) 762 _+ 24 764 + 18 772 + 18 
SDNN (ms) 124 + 9 119 + 7 115 + 6 
CV (~b) 16.5 + 1.0 16.0 + 0.8 15.2 +- 0.8 
rMSSD (ms) 20 + 2 21 + 2 20 + 2 
pNN50 (C}) 3.6 + 1.0 3.4 + 0.7 3.1 +_ 0.9 
Frequency, domain variablcs 
TP(abs) (ms el 2,14(I + 290 2,356 + 233 2,491 + 355 
LF(abs) (ms =) 431 + 82 442 -+ 64 470 + 99 
HF(abs) (ms-') 148 +_ 4(I 153 -+ 30 133 -+ 30 
LF(nu) (%) 56.5 + 13~ 56.1 +_ 2.(I 55.7 + 2.3 
HF(nu) (~:,~) ltl.ti + 1,7 20.3 _+ 1.8 19.2 +_ 1.6 
LF/HF ratio 4.5 +: 11.6 4.3 -+ 0.4 4.4 _+ 0.6 
*Median (range). Data presented are mean value _+ SEM, unless otherwise indicated. Abbreviations as in Table 1. 
analysis of variance and the Student t test. The Scheffd 
procedure was used in the analysis of variance to correct for 
multiple comparisons. For nonnormally distributed variables, 
the Kruskal-Wallis and Wilcoxon signed rank tests w re used. 
All p values are reported for two-tailed tests, and an alpha 
<0.05 was considered statistically significant. Mean values of 
variables of heart rate variability were calculated for the entire 
24-h period. To assess the differential effects of drug treatment 
during both daytime and nighttime, periods from midnight to 
8 AM (nighttime) and from 8 AM to noon (daytime) were 
analyzed separately. Linear regression analysis w s used to test 
the relation between values of variables of heart rate variability 
at baseline and after treatment. 
Resu l t s  
Study patients. Of the original DIMT study patients (18), 
Holter recordings for analysis of heart rate variability were 
available in 71 at baseline and after 3-month follow-up. Holter 
recordings could not be analyzed for heart rate variability in 12 
patients because ectopic beats or noise accounted for >15% of 
the signal at baseline (7 patients [placebo in 2, digoxin in 2, 
ibopamine in 3] or during follow-up (5 patients [placebo in 3, 
ibopamine in 2]). Therefore, the remaining 59 patients consti- 
tuted the study group and underwent heart rate variability 
analysis both at baseline and after 3 months. T ere were no 
significant differences at baseline among the three treatment 
groups, with respect to clinical characteristics and variables of 
heart rate variability (Table 2). Three patients had non- 
insulin-dependent diabetes mellitus (placebo in 1, digoxin in 1, 
ibopamine in 1). Heart failure was present for a median of 7.5 
months. Comparison of the baseline characteristics of this 
subgroup with those of the original DIMT study cohort 
revealed no significant differences. 
Neurohormonal levels. After 3 months of treatment, 
plasma norepinephrine l vels had increased in the placebo 
group (+31 pg/ml), whereas they had decreased in both the 
digoxin ( 60 pg/ml, p < 0.01 vs. placebo) and ibopamine 
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Figure 1. Change in plasma neurohormone l vels after 3 months of 
treatment, expressed as percent of baseline values. Solid bars = 
placebo; crosshatched bars = digoxin; hatched bars = ibopamine. 
**p < 0.01 versus placebo. 
groups ( -27 pg/ml, p = 0.10 vs. placebo). After digoxin and 
ibopamine therapy, a trend was observed for changes in 
aldosterone and renin opposite to those in the placebo group; 
however, these changes did not reach statistical significance 
(Fig. 1). 
Variables of heart rate variability. After 3 months of 
treatment, all time domain variables were decreased in the 
placebo group compared with baseline values (Table 3, Fig. 2). 
In contrast, an overall increase was observed in the digoxin 
group. Compared with the placebo group, the mean value of 
normal RR intervals increased significantly, as did the standard 
deviation of normal RR intervals (SDNN). The standard 
deviation adjusted for the change in mean value of normal RR 
intervals (i.e., coetficient of variance) showed no significant 
change. The root mean square successive differences (rMSSD) 
and percent difference between successive normal RR intervals 
>50 ms (pNN50) were significantly enhanced by digoxin. In 
[ 
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Figure 2. Change in time domain (top) and frequency domain vari- 
ables (bottom) of heart rate variability after 3 months of treatment, 
expressed as percent of baseline values, abs = absolute units; CV = 
coelficient of variance; HF = high frequency power; LF = low 
frequency power; NN = normal RR intervals; nu = normalized units; 
pNN50 = percent difference between successive normal RR intervals 
>50 ms; rMSSD = root mean square of successive difference; SDNN 
- standard deviation of normal RR intervals; TP = total power. 
Symbols as in Figure 1. *p < 0.05, **p < 0.01 versus placebo. 
Table 3. Changes in Variables of Heart Rate Variability After 3 
Months of Treatment 
Placebo Digoxin Ibopamine 
Variable (n = 18) (n = 22) (n = 19) 
Time domain 
Mean NN (ms) 1 + 10 *55 + 11' -6  + 12 
SDNN (ms) 10 _+ 6 + 14 _+ 7+ -3  + 8 
CV (%) -1 .4  + 0.7 -(I.7 + (1.8 +(I.4 _+ 1.1 
rMSSD (ms) 1 ± I +3 + 2* - I  _+ 2 
pNN50 (%) 1).7 + 0.t~ - 1.7 + 0.9* +(}.6 + ().7 
Frequency domain 
TP(abs) (ms 2) 84 + 159 *332 + 125+ 92 ± 270 
LF(abs) (ms 2) 39 + 48 +54 ± 32+ -34  + 93 
HF(abs)  (ms 2) -12  + 22 ~-40 -~ 33* +8 + 43 
LF(nu) (%) -1 .3  + l.II -2 . [  + 1.3 +0.1 + 1.4 
HF(nu)  (%) 0.2 ~ 0.9 ~2.4 ~ 1.7+ +1.7 _+ 1.3 
LF /HF  ratio -0 .2  + 0.3 0.5 + 0.3t 0.4 -+ 0.3 
*p < 0.01, tp < 0.05 versus placebo. Data presented are mean change 
relative to baseline _+ SEM. + = increase: - = decrease: abbreviations as in 
Table 1. 
the ibopamine group, similar but nonsignificant trends oppo- 
site to the decrease in the placebo group were observed. 
Spectral analysis of heart rate variability showed a decrease 
in all variables in the placebo group similar to the change in 
time domain variables, except for a small increase in the ratio 
of low to high frequency power. In the digoxin group, total 
power, and low and especially high frequency power showed a 
significant increase (absolute units). Normalized high fre- 
quency power also showed a significant increase, whereas 
normalized low frequency power showed a nonsignificant trend 
to decrease. The ratio of low to high frequency power was 
significantly reduced after digoxin. In the ibopamine group, 
again, less pronounced and nonsignificant changes were ob- 
served. Comparison of the individual changes in plasma neu- 
rohormone levels and variables of heart rate variability re- 
vealed no significant correlations, either in the total group or in 
any of the three treatment groups. 
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Table 4. Differential Effects of Digoxin on Heart Rate Variability During Nighttime and Daytime 
Nighttime Daytime 
Variable Baseline 3 mo Baseline 3 mo 
Time domain 
Mean NN (ms) 842 _+ 22 907 _+ 25* 717 _+ 19 772 _+ 
rMSSD (ms) 23 -+ 2 24 + 2 20 -+ 1 23 - 
pNN50 (%) 3.8 + 0.9 5.4 + 1.3 2.9 -+ 0.7 4.9 -+ 
Frequency domain 
TP(abs) (ms 2) 2,736 _+ 297 2,906 _+ 380 2,070 -+ 269 2,605 +_ 
LF(abs) (ms 2) 520 + 76 567 + 88 389 _+ 71 479 + 
HF(abs) (ms 2) 186 _+ 45 207 +_ 34 117 + 22 175 _+ 
LF(nu) (%) 52.9 _+ 2.2 5t.0 _+ 1.9 58.0 _+ 2.0 56.5 _+ 
HF(nu) (%) 22.3 _+ 2.2 24.3 _+ 2.1 18.9 _+ 1.6 21.7 _+ 
LF/HF ratio 4.2 + 0.5 3.6 + 0.4 4.5 _+ 0.4 3.9 _+ 
23~ 
2* 
1.2~ 
348* 
83¢ 
34* 
1.8 
1.8~ 
0.3 
*p < 0.01, tp < 0.001, :~p < 0.05 versus baseline. Data presented are mean value _+ SEM. Abbreviations as in Table 1. 
The effects of digoxin on variables of heart rate variability 
during nighttime and daytime are shown in Table 4.Compared 
with that at baseline, the mean value of normal RR inter- 
vals was significantly prolonged during both nighttime and 
daytime. However, significant changes in variables of heart rate 
variability were observed during daytime hours only. The 
rMSSD and pNN50 values, which showed lower values at 
baseline during the day than at night, were significantly en- 
hanced in the daytime hours during digoxin treatment. Similar 
changes were observed in frequency domain variables. Both 
absolute and normalized high frequency components were 
significantly enhanced with digoxin treatment during the day- 
time, but changes in heart rate variability after placebo and 
ibopamine treatment were not significant during either night- 
time or daytime. 
Comparison of the baseline values of heart rate variability 
and the subsequent change during treatment revealed an 
inverse relation for several variables in the digoxin-treated 
patients. A statistically significant negative corr lation was 
observed for rMSSD, normalized low frequency power, abso- 
lute and normalized high frequency power and the ratio of low 
to high frequency power (Table 5). In the ibopamine-treated 
patients, a statistically significant negative corr lation was 
found for the ratio of low to high frequency power only (r = 
Table 5. Correlation Between Variables of Heart Rate Variability, at 
Baseline and After 3 Months of Treatment in the Digoxin Group 
(n = 22) 
r Value p Value 
rMSSD (ms) (I.53 0.012 
HF(abs) (ms 2) -0.53 0.011 
LF(nu) (%) -051 0./117 
HF(nu) (%) -0.49 0.022 
LFMF ratio -(I.68 < 0.001 
Only significant correlations are listed: r values obtained using least squares 
linear regression analysis. Abbreviations as in Table 1. 
-0.48, p = 0.045), not for the other variables. No significant 
trends were observed in the placebo group. Scatterplots of the 
correlation between the ratio of low to high frequency power 
and at baseline and after 3 months of treatment for the 
placebo, digoxin a d ibopamine groups are shown in Figure 3. 
Discuss ion  
To our knowledge, the present study is the first to report 
placebo-controlled ata on the effects of treatment with 
digoxin and ibopamine on variables of heart rate variability in 
heart failure. In patients with mild to moderate heart failure, 
treatment with digoxin was found to prevent the progressive 
deterioration i variables of heart rate variability that was 
observed in placebo-treated patients. In addition, digoxin 
prevented the increase in neurohormonal activation that was 
observed in the placebo group. An important novel finding in 
our study is that digoxin treatment enhances variables of heart 
rate variability associated with cardiac vagal tone especially 
during daytime, when sympathetic tone is known to be in- 
creased and parasympathetic tone is decreased (24). Further- 
more, the treatment effect is inversely correlated with a 
number of variables of heart rate variability at baseline, and 
digoxin therefore seems to exert its effect on autonomic 
control, especially when these variables are impaired. As 
mentioned earlier, there were no changes in exercise capacity 
and symptom scores after 3 months of digoxin treatment, 
which makes it unlikely that differences in activity canexplain 
the observed differences in heart rate variability (18). These 
effects indicate a modulating influence on autonomic tone, 
which agrees with earlier reports of the neurohormonal- 
modulating effects of digoxin (24-26). Furthermore, our re- 
sults are concordant with the recently published study of Krum 
et al. (17) in patients with chronic heart failure. After treat- 
ment with digoxin, they also found a significant decrease in 
plasma norepinephrine l vels combined with a significant 
enhancement of parasympathetic activity. However, a placebo 
control group was not included in their study. After ibopamine, 
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Figure 3. Scatterplot f correlation between low frequency/high fre- 
quency (LF/HF) ratio at baseline and change after 3 months of 
treatment i  the placebo, digoxin and ibopamine groups. 
only nonsignificant trends opposite to the deterioration i  the 
placebo group were observed, both in variables of heart rate 
variability and in neurohormonal activation. 
Variables of heart rate variability. Compared with the 
decline in the placebo group after 3 months in our study, 
digoxin significantly improved variables of heart rate variabil- 
ity. Ibopamine did not show a statistically significant effect on 
these variables. The variables associated with cardiac vagal 
control (rMSSD, pNN50 and high frequency power) showed a 
significant increase with digoxin c mpared with placebo. These 
results indicate a p rasympathomimetic ffect of digoxin in 
patients with heart failure, which confirms the findings in 
experimental studies (26,27). Furthermore, our data are in 
agreement with the findings of Kaufman et al. (28), who 
showed that short-term treatment with digoxin in healthy 
volunteers induced increases in variables of heart rate variabil- 
ity parameters up to 51%, particularly in indexes of vagal 
modulation. Similar to the findings of Ferguson et al. (27), we 
found a small but significant increase in themean normal-to- 
normal interval, that could be considered a direct result of the 
shifted sympathovagal balance. Th  observed increase in ab- 
solute high frequency power may in part be explained by this 
increase in the mean normal-to-normal interval and parallels 
the observed increases in SDNN and total power. Still, high 
frequency power shows also a significant increase expressed in 
normalized units. Furthermore, the increase in absolute and 
normalized high frequency power during the day was signifi- 
cant. Absolute low frequency power also showed a significant 
increase, but normalized low frequency power showed a trend 
to decrease. Because th ratio f low to high frequency power 
showed a trend to decrease, the digoxin-induced changes in 
variables of heart rate variability can be considered to reflect a 
shift in sympathovagal balance toward enh nced cardiac vagal 
tone (29). 
There are no previous reports on the effects of ibopamine 
on variables of heart rate variability. In the present study, 
trends opposite to those in the placebo group were observed in 
ibopamine-treated patients for both variables of heart rate 
variability and neurohormonal activation. In the present study, 
none of these changes reached statistical significance; but
previous data (18,30,32) suggest a significant decrease in 
neurohormone levels during treatment with ibopamine com- 
pared with placebo. Because this study was carried out in 
patients with mild disease, and the sample size was limited, 
further studies will be needed to better establish the effects of 
ibopamine on heart rate variability. 
The effects of drug therapy on variables of heart rate 
variability in patients with heart failure have been addressed in
three previous studies (14-16). Angiotensin-converting en- 
zyme inhibitors (14,15) were found to improve overall heart 
rate variabili~ especially in association with vagal control. In a 
study by Coumel et al. (16), beta-blockers also improved th  
imbalance of the autonomic nervous system, as was shown by 
changes in the heart rate variability spectrum. However, th  
effect of treatment on neurohormonal ctivation was not 
evaluated in those previous studies. Nevertheless, b cause 
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both drugs have been shown to reduce neurohormonal activa- 
tion (33), our results are basically in accord with the aforemen- 
tioned studies (14-16). 
Neurohormonal activation. There is now accumulating ev- 
idence that neurohormonal ctivation is not simply a marker of 
the severity of heart failure, but that it may actually contribute 
to the progression of the disease and therefore may have prog- 
nostic significance (33,34). As a consequence, drugs thatpossess 
neurohormonal-inhibiting properties, such as angiotensin- 
converting enzyme inhibitors (35,36), digoxin (18,25), beta- 
blockers (37) and oral dopaminergic agents (18,30-32), have 
recently gained increasing attention. Indeed, the former two 
drugs appear to be beneficial in the long-term treatment of 
patients with heart failure. It has been suggested (33,38) that a 
neurohormonal modulating effect of these drugs may be more 
important han a beneficial hemodynamic nfluence. Neuro- 
hormonal activation may lead to progressive autonomic im- 
pairment and baroreceptor dysfunction (39), and it may be 
hypothesized that reversal of neurohormonal ctivation may 
correct hese abnormalities. 
Furthermore, it should be emphasized that our study was 
performed in patients with mild disease. In these patients, 
treatment with digoxin improved the progressive disturbance 
in parasympathetic control of the heart that was observed in 
placebo-treated patients. In patients with a roughly similar, 
"early," degree of heart failure, Binkley et al. (15) also showed 
augmentation of cardiac vagal tone after treatment with an 
angiotensin-converting e zyme inhibitor. Both studies uggest 
that drug treatment may be beneficial early in the disease 
process of heart failure, because it may restore the observed 
derangement in autonomic ontrol. 
Other studies (7,10) have shown that impairment of heart 
rate variability and autonomic function in heart failure are 
correlated with the degree of neurohormonal ctivation. Al- 
though our data suggest that this neurohormonai effect may be 
responsible for the observed improvement in heart rate vari- 
ability, no direct correlations between individual changes in 
variables of heart rate variability and plasma neurohormone 
levels were found. This result agrees with a recent report from 
Adamopoulos et al. (11), who showed that in patients with 
heart failure, an overall decrease in neurohormonal ctivation 
was related to an overall improvement in variables of heart 
rate variability but that no significant individual correlations 
were present. In fact, they concluded that specific variables of 
autonomic function reflect different aspects of circulatory 
control (11). 
Clinical implications. Improvement in heart rate variabil- 
ity by drug treatment may be important irrespective of changes 
in neurohormonal ctivation because recent studies (13) indi- 
cate that impaired heart rate variability is independently 
related to an adverse prognosis in patients with heart failure. 
Although we did not investigate the prognostic value of this 
change in heart rate variability, the drug-induced improvement 
in heart rate variability in the present study may shed new light 
on the value of digoxin in this syndrome. The benefit of digoxin 
treatment has been questioned in patients with heart failure 
who are in sinus rhythm (40). Our finding that digoxin appar- 
ently affects heart rate variability under circumstances a soci- 
ated with neuroendocrine activation may well be compatible 
with reports (40) indicating that patients with more severe 
heart failure derive benefit from digoxin treatment. The ob- 
served negative correlation between heart rate variability at 
baseline and after t eatment also suggests that analysis of heart 
rate variability may be used to identify patients with heart 
failure who will benefit from drug treatment. Further studies 
will be needed to evaluate the clinical consequences of these 
findings. 
We thank W. Arnold Dijk, MSc, Bert J. M. Mulder, MSc, and Jan W. Viersma, 
MD for their technical support and assistance in this study. 
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